patent.fyi
Applications  /  US 2026/0355388
United States Patent Application Publication

US 2026/0355388 A1

Published
Nov 12, 2026
Filed
Oct 11, 2023
Earliest date on the face
Oct 11, 2022
Classification
A61L 27/3813
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Membrane separates graft cells

What ifWhat if the cells retain normal MHC class I levels and function and a porous membrane separates them from host immune cells?
Claim language“a reduction in the level or function”

A semipermeable membrane encloses the graft cells. Oxygen, nutrients, and secreted peptides diffuse across it, while the pores prevent host immune cells from making direct contact with the graft.

1.1Recipient supplies the cells

What ifWhat if the engineered cells come from the recipient and retain normal MHC class I levels and function?
Claim language“a reduction in the level or function”

A biopsy provides dermal fibroblasts for expansion and engineering before implantation in the same recipient. The fibroblasts retain the recipient’s own MHC class I molecules, so the graft introduces no donor MHC class I mismatch.

1.2Reservoir releases a protein

What ifWhat if a reservoir in the implant supplies a preformed therapeutic protein and the cells carry no introduced sequence encoding it?
Claim language“an exogenous nucleic acid encoding a therapeutic agent”

A sealed reservoir holds a sterile solution of the therapeutic protein. A rate-controlling membrane meters diffusion into the surrounding tissue, and the loaded volume sets the supply available between refills.

1.2Native gene supplies insulin

What ifWhat if implanted pancreatic beta cells supply insulin from their native insulin gene with no introduced insulin coding sequence?
Claim language“an exogenous nucleic acid encoding a therapeutic agent”

Glucose enters the beta cells and raises their intracellular ATP concentration. The resulting membrane depolarization opens voltage-gated calcium channels, and calcium entry triggers release of insulin from secretory granules.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Automated or data-driven variant

Automated measurement of cassette secretion

A flow-through test fixture holds the assembled implant and circulates culture medium across its outer membrane before implantation. A controller logs the flow rate and collects paired inlet and outlet samples at fixed intervals for an assay specific to the therapeutic agent. Software multiplies the outlet-minus-inlet concentration difference by the measured flow rate to calculate the agent's net appearance rate in the medium once the readings stabilize.

Specific version of a part

Reduced class I assembly

The engineered cells express less beta-2 microglobulin, a subunit of most classical MHC class I complexes. Lower subunit availability reduces the number of stable complexes at the cell surface.

Introduced insulin coding sequence

An introduced DNA cassette in a pancreatic beta cell contains a human preproinsulin coding sequence. The cell processes the precursor into insulin and stores it in secretory granules.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2020/0246760 A1
Published
Aug 6, 2020
Filed
Feb 28, 2020
Class
B01D 71/68
Document BUS 2020/0407694 A1
Published
Dec 31, 2020
Filed
Apr 16, 2018
Class
C12N 5/10
Claim 1
Document A
Document B
1.1(i) the engineered mammalian cell comprises a reduction in the level or function of a major histocompatibility complex (MHC) class I protein complex; and
Method according to the previous one, wherein said endogenous locus is a locus expressing a MHC I component, such as β2m. Method according to the previous one, wherein said insertion of said exogenous sequence inactivates β2m expression at said endogenous locus Method according to the previous ones, wherein said endogenous promoter is selected to be active during immune cell activation.
B · US 2020/0407694 A1 · ¶ 199
1.2(ii) the engineered mammalian cell comprises an exogenous nucleic acid encoding a therapeutic agent;
Specifically, a gene encoding an amino acid sequence of predetermined recombinant gelatin is acquired, the acquired gene is incorporated into an expression vector to produce a recombinant expression vector, and a transformant is produced by introducing the recombinant expression vector into an appropriate host.
A · US 2020/0246760 A1 · ¶ 90
More specifically, the invention is drawn to a method for preparing engineered primary immune cells for cell immunotherapy, said method comprising: providing a population of primary immune cells; introducing into a proportion of said primary immune cells: i) At least one exogenous nucleic acid comprising an exogenous coding sequence encoding at least one molecule improving the therapeutic potential of said immune cells population; ii) At least one sequence-specific nuclease r
B · US 2020/0407694 A1 · ¶ 109
1.3wherein the implantable element comprises a polymer and a compound of Formula (I):
The porous membrane may contain other components other than polymers as additives.
A · US 2020/0246760 A1 · ¶ 182

An empty cell means only that no passage was reproduced there.

Statements in these documents
It has been recognized as a problem that a cell transplant device cannot sufficiently function unless blood vessels are formed around the cell transplant device in order to allow continuous supplying of nutrients to transplanted biological constituents and secretion of physiologically active substances from the transplanted biological constituents, and therefore various studies have been conducted.
A · US 2020/0246760 A1 · ¶ 5
An object of the present invention is to provide a cell transplant device having an ability to induce angiogenesis around the cell transplant device, and a method for manufacturing the same.
A · US 2020/0246760 A1 · ¶ 7
The method of the invention contributes to improving the therapeutic potential and safety of engineered primary immune cells for their efficient use in cell therapy.
B · US 2020/0407694 A1 · ¶ 3
However, most of these clinical trials have used immune cells, mainly NK and T-cells, obtained from the patients themselves or from compatible donors, bringing some limitations with respect to the number of available immune cells, their fitness, and their efficiency to overcome diseases that have already developed strategies to get around or reduce patient's immune system.
B · US 2020/0407694 A1 · ¶ 5
Cite aspatent.fyi, US 2026/0355388 A1, claim 1, first published 2026-11-19T10:59:45-05:00, https://patent.fyi/US20260355388/, SHA-256 85aee713d72f75893e224b70b757847a2e88c0d7f57f3e1c10ad62ad43ed882d
First published
Permanent addresshttps://patent.fyi/US20260355388/
Content fingerprint (SHA-256)85aee713d72f75893e224b70b757847a2e88c0d7f57f3e1c10ad62ad43ed882d
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi